July 26 (Reuters) - Gilead Sciences Inc said on Wednesday its second-quarter profit fell 12 percent as use of its flagship hepatitis C drugs continued to decline, but the results beat Wall Street estimates and the company raised its full-year sales outlook.
Shares of Gilead, which closed at $74.19 on Nasdaq, rose 2.2 percent to $75.72 after hours.
After one-time items, Gilead earned $2.56 a share. Wall Street analysts, on average, had forecast adjusted earnings of $2.15 a share, according to Thomson Reuters I/B/E/S.
Quarterly sales of hepatitis C drugs Sovaldi, Harvoni and Epclusa totaled $2.9 billion, down from $4 billion a year earlier. Analysts had forecast $2.23 billion. (Reporting by Deena Beasley; Editing by Richard Chang)